Resolution of acute inflammation in the lung

Annual Review of Physiology

Volumn 76, Issue , 2014, Pages 467-492

  Levy, Bruce D ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute respiratory distress syndrome; Asthma; Catabasis; Efferocytosis; Lipoxin; Maresin; Pneumonia; Polyunsaturated fatty acid; Proresolving mediators; Protectin; Resolvin

Indexed keywords

ACUTE DISEASE; ANIMALS; ANTIGENS, CD59; ASTHMA; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION MEDIATORS; LIPOXINS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84894220883     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170408     Document Type: Review

References (149)

1. Majno G, Joris I. 1996. Cells, Tissues andDisease: Principles of General Pathology.Cambridge,UK: Blackwell Sci..
2. Ward PA. 2010. Acute and chronic inflammation. In Fundamentals of Inflammation, ed. CNSerhan, PA Ward, DWGilroy, pp. 1-16. Cambridge, UK: Cambridge Univ. Presss
3. Serhan CN, Savill J. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6:1191-977
4. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, et al. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21:325-322
5. Serhan CN,ClishCB, Brannon J,Colgan SP, ChiangN,Gronert K. 2000. Novel functional sets of lipidderived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192:1197-2044
6. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, et al. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196:1025-377
7. Tabas I, Glass CK. 2013. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-722
8. Bannenberg G, Serhan CN. 2010. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801:1260-733
9. SerhanCN,Petasis NA. 2011. Resolvins and protectins in inflammation resolution. Chem. Rev. 111:5922-433
10. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Investig. 101:890-988
11. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, et al. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174:4345-555
12. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. 2006. Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress proinflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281:38376-844
13. Ariel A, Li P-L, Wang W, Tang W-X, Fredman G, et al. 2005. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280:43079-866
14. Ariel A, Fredman G, Sun Y-P, Kantarci A, Van Dyke TE, et al. 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7:1209-166
15. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, et al. 2013. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5:1-111
16. Haworth O, CernadasM, Levy BD. 2011. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J. Immunol. 186:6129-355
17. Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. 2008. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 112:2512-199
18. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. 2011. Cutting edge: humanized nano-proresolving medicines mimic inflammation- resolution and enhance wound healing. J. Immunol. 186:5543-477
19. Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN. 2011. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 25:544-600
20. Krishnamoorthy S, Recchiuti A, ChiangN, Fredman G, Serhan CN. 2012. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am. J. Pathol. 180:2018-277
21. Schwab JM, ChiangN, Arita M, Serhan CN. 2007. Resolvin E1 and protectin D1 activate inflammationresolution programmes. Nature 447:869-744
22. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. 2008. Resolvin E1 regulates interleukin 23, interferon-and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9:873-799
23. Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, GilroyDW,Bystrom J. 2010. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184:1516-255
24. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171-766
25. Flower RJ. 2006. Prostaglandins, bioassay and inflammation. Br. J. Pharmacol. 147(Suppl. 1):S182-922
26. Serhan CN, Hamberg M, Samuelsson B. 1984. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 81:5335-399
27. Serhan CN, Chiang N, Van Dyke TE. 2008. Resolving inflammation: dual anti-inflammatory and proresolution lipid mediators. Nat. Rev. Immunol. 8:349-611
28. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:612-199
29. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD. 2005. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174:5033-399
30. DuftonN,HannonR, BrancaleoneV,Dalli J, PatelHB, et al. 2010. Anti-inflammatory role of themurine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184:2611-199
31. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, et al. 2012. Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc. Natl. Acad. Sci. USA 109:935-400
32. Serhan CN. 2007. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25:101-377
33. BrezinskiME, Serhan CN. 1990. Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl. Acad. Sci. USA 87:6248-522
34. Kasuga K, Yang R, Porter TF,Agrawal N, PetasisNA, et al. 2008. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181:8677-877
35. Serhan CN. 2011. The resolution of inflammation: the devil in the flask and in the details. FASEB J. 25:1441-488
36. Chan MM, Moore AR. 2010. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184:6418-266
37. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-7011
38. Karp CL, Flick LM, Park KW, Softic S, Greer TM, et al. 2004. Defective lipoxin-mediated antiinflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5:388-922
39. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, et al. 2005. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. CareMed. 172:824-300
40. Kunkel SL, Ogawa H, Conran PB, Ward PA, Zurier RB. 1981. Suppression of acute and chronic inflammation by orally administered prostaglandins. Arthritis Rheum. 24:1151-588
41. Perretti M, Chiang N, La M, Fierro IM, Marullo S, et al. 2002. Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8:1296-3022
42. Perretti M, Dalli J. 2009. Exploiting the annexin A1 pathway for the development of novel antiinflammatory therapeutics. Br. J. Pharmacol. 158:936-466
43. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. 2001. Possible new role for NF-B in the resolution of inflammation. Nat. Med. 7:1291-977
44. Leitch AE, Lucas CD, Marwick JA, Duffin R, Haslett C, Rossi AG. 2012. Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ. 19:1950-611
45. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. 2013. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br. J. Dermatol. 168:172-788
46. US Natl. Inst. Health. 2010. ClinicalTrials.gov: clinical studies. Identifier: NCT00799552; http:// clinicaltrials.govv
47. Serhan CN, Haeggstrom JZ, Leslie CC. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-588
48. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, et al. 2007. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282:9323-344
49. Serhan CN, YangR,MartinodK,Kasuga K, Pillai PS, et al. 2009. Maresins: novel macrophagemediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206:15-233
50. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, et al. 2011. The human serum metabolome. PLoS One 6:e169577
51. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, et al. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201:713-222
52. Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN. 2012. Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 188:4527-344
53. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, et al. 2006. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13:1193-2022
54. Mas E, Croft KD, Zahra P, Barden A, Mori TA. 2012. Resolvins D1, D2, and other mediators of selflimited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58:1476-844
55. Edenius C, Kumlin M, Bjork T, Anggard A, Lindgren JA. 1990. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett. 272:25-288
56. Gronert K, Gewirtz A, Madara JL, Serhan CN. 1998. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon-and inhibits tumor necrosis factor induced IL-8 release. J. Exp. Med. 187:1285-944
57. Levy BD,RomanoM,Chapman HA,Reilly JJ, Drazen J, SerhanCN. 1993.Humanalveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Investig. 92:1572-799
58. Romano M, Serhan CN. 1992. Lipoxin generation by permeabilized human platelets. Biochemistry 31:8269-777
59. Serhan CN, Sheppard KA. 1990. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Investig. 85:772-800
60. Fiore S, SerhanCN. 1990. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 172:1451-577
61. MayadasTN, Mendrick DL, Brady HR, Tang T, Papayianni A, et al. 1996. Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 49:1342-499
62. Weissmann G. 1991. Aspirin. Sci. Am. 264:84-900
63. Claria J, Serhan CN. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92:9475-799
64. Claria J, LeeMH, Serhan CN. 1996. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 2:583-966
65. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. 2004. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101:15178-833
66. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, et al. 2009. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183:2089-966
67. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, et al. 2006. Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. Circulation 114:929-355
68. Planaguma A, Pfeffer MA, Rubin G, Croze R, UddinM, et al. 2010. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol. 3:270-79 107(10):1170-844
69. SpiteM, Serhan CN. 2010. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ. Res. 107(10):1170-844
70. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. 2000. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164:1663-677
71. Maddox JF,HachichaM,TakanoT, Petasis NA, Fokin VV, Serhan CN. 1997. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272:6972-788
72. Serhan CN,Hamberg M, Samuelsson B. 1984. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Biophys. Res. Commun. 118:943-499
73. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. 1998. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Investig. 101:819-266
74. Gong J, Rosner B, Rees DG, Berson EL, Weigel-DiFranco CA, Schaefer EJ. 1992. Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 33:2596-6022
75. Newcomer LM, King IB, Wicklund KG, Stanford JL. 2001. The association of fatty acids with prostate cancer risk. Prostate 47:262-688
76. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, et al. 2002. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346:1113-188
77. Kew S, Mesa MD, Tricon S, Buckley R, Minihane AM, Yaqoob P. 2004. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am. J. Clin. Nutr. 79:674-811
78. Wakai K, Ito Y, Kojima M, Tokudome S, Ozasa K, et al. 2005. Intake frequency of fish and serum levels of long-chain n-3 fatty acids: a cross-sectional study within the Japan Collaborative Cohort Study. J. Epidemiol. 15:211-188
79. De Caterina R. 2011. n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364:2439-500
80. Iigo M, Nakagawa T, Ishikawa C, Iwahori Y, Asamoto M, et al. 1997. Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br. J. Cancer 75:650-555
81. Burr GO, Burr MM. 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82:345-677
82. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. 2011. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Investig. 121:569-811
83. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N. 2000. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J. Physiol. Pharmacol. 51:643-544
84. Ogawa S, Urabe D, Yokokura Y, Arai H, Arita M, Inoue M. 2009. Total synthesis and bioactivity of resolvin E2. Org. Lett. 11:3602-55
85. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, et al. 2013. Stereochemical assignment and antiinflammatory properties of the omega-3 lipid mediator resolvin E3. J. Biochem. 153:355-600
86. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, et al. 2012. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J. Biol. Chem. 287:10525-344
87. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. 2003. Novel docosatrienes and 17Sresolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278:14677-877
88. Spite M, Norling LV, Summers L, Yang R, Cooper D, et al. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:1287-911
89. Dalli J, Winkler JW, Colas RA, ArnardottirH,Cheng CY, et al. 2013. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem. Biol. 20:188-2011
90. Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, et al. 2012. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484:524-288
91. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, et al. 2006. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176:1848-599
92. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, et al. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278:43807-177
93. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, et al. 2011. Novel proresolving aspirintriggered DHA pathway. Chem. Biol. 18:976-877
94. Gordon S. 2007. The macrophage: past, present and future. Eur. J. Immunol. 37:S9-177
95. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, et al. 2012. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26:1755-655
96. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, et al. 2013. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 27:2573-833
97. ChiangN, Serhan CN, Dahlen SE, Drazen JM, Hay DW, et al. 2006. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58:463-877
98. Fiore S,Maddox JF, PerezHD,SerhanCN. 1994. Identification of a human cDNAencoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180:253-600
99. Krishnamoorthy S, Recchiuti A, ChiangN, Yacoubian S, Lee CH, et al. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107:1660-655
100. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, et al. 2009. International Union of Basic and Clinical Pharmacology LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61:119-611
101. Fiore S, Ryeom SW,Weller PF, Serhan CN. 1992. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J. Biol. Chem. 267:16168-766
102. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. 1997. Aspirin-triggered 15-epilipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693-7044
103. Chiang N, Takano T, Arita M, Watanabe S, Serhan CN. 2003. A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol. 139:89-988
104. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, et al. 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17:652-599
105. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, et al. 2002. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. 8:1018-233
106. Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, et al. 2010. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. USA 107:8842-477
107. Simiele F, Recchiuti A, Mattoscio D, De Luca A, Cianci E, et al. 2011. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 26:1323-333
108. Levy BD, Vachier I, SerhanCN. 2012. Resolution of inflammation in asthma. Clin. Chest Med. 33:559-700
109. Gronert K,Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN. 2001. Selectivity of recombinant human leukotrieneD4, leukotriene B4, and lipoxin A4 receptors with aspirin-triggered 15-epi-LXA4 and regulation of vascular and inflammatory responses. Am. J. Pathol. 158:3-99
110. Pamplona FA, Ferreira J, Menezes de Lima O Jr, Duarte FS, Bento AF, et al. 2012. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl. Acad. Sci. USA 109:21134-399
111. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, et al. 2003. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198:977-855
112. Campbell EL, LouisNA, Tomassetti SE,Canny GO, AritaM, et al. 2007. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21:3162-700
113. Cash JL, Hart R, Russ A, Dixon JP, Colledge WH, et al. 2008. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205:767-755
114. Du XY, Leung LL. 2009. Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim. Biophys. Sin. 41:973-799
115. Luangsay S,Wittamer V, Bondue B, De Henau O, Rouger L, et al. 2009. Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J. Immunol. 183:6489-999
116. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. 2007. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178:3912-177
117. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, et al. 2003. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55:195-2277
118. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. 2012. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32:1970-788
119. Marcheselli VL, Mukherjee PK, Arita M, Hong S, Antony R, et al. 2010. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 82:27-344
120. Fredman G, Serhan CN. 2011. Specialized pro-resolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem. J. 437:185-977
121. Butler KL, Ambravaneswaran V, Agrawal N, Bilodeau M, Toner M, et al. 2012. Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS One 5:e119211
122. Dona M, FredmanG, Schwab JM, ChiangN, Arita M, et al. 2008. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112:848-555
123. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. 2009. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 285:3451-611
124. Ramon S, Gao F, Serhan CN, Phipps RP. 2012. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J. Immunol. 189:1036-422
125. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, et al. 2010. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16:592-977
126. Maderna P, Cottell DC, Berlasconi G, Petasis NA, Brady HR, Godson C. 2002. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am. J. Pathol. 160:2275-833
127. Reville K, Crean JK, Vivers S, Dransfield I, Godson C. 2006. Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J. Immunol. 176:1878-888
128. Jones CN, Dalli J, Dimisko L,Wong E, Serhan CN, Irimia D. 2012. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc. Natl. Acad. Sci. USA 109:20560-655
129. Kurihara T, Jones CN, Yu YM, Fischman AJ, Watada S, et al. 2013. Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J. 27:2270-811
130. Carlo T, Kalwa H, Levy BD. 2013. 15-Epi-lipoxin A4 inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1. FASEB J. 27:2733-411
131. Levy BD, Petasis NA, Serhan CN. 1997. Polyisoprenyl phosphates in intracellular signalling. Nature 389:985-900
132. Bonnans C, Fukunaga K, Keledjian R, Petasis NA, Levy BD. 2006. Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury. J. Exp. Med. 203:857-633
133. Levy BD, Fokin VV, Clark JM, Wakelam MJ, Petasis NA, Serhan CN. 1999. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipaseDactivity: a "stop" signaling switch for aspirin-triggered lipoxin A4. FASEB J. 13:903-111
134. Carlo T, Petasis NA, Levy BD. 2009. Activation of polyisoprenyl diphosphate phosphatase 1 remodels cellular presqualene diphosphate. Biochemistry 48:2997-30044
135. Fukunaga K, AritaM, Takahashi M, Morris AJ, Pfeffer M, Levy BD. 2006. Identification and functional characterization of a presqualene diphosphate phosphatase. J. Biol. Chem. 281:9490-977
136. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, et al. 2013. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J. Allergy Clin. Immunol. 132:547-533
137. Lee TH, Crea AE, Gant V, Spur BW, Marron BE, et al. 1990. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Respir. Dis. 141:1453-588
138. Vachier I, Bonnans C, Chavis C, FarceM, Godard P, et al. 2005. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol. 115:55-600
139. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, et al. 2000. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16:44-499
140. Planaguma A,Kazani S,Marigowda G, HaworthO,MarianiTJ, et al. 2008. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma.Am. J. Respir. Crit.CareMed. 178:574-822
141. Christie PE, Spur BW, LeeTH. 1992. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 145:1281-844
142. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, et al. 2004. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350:560-699
143. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, et al. 2007. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178:496-5022
144. Kowal-Bielecka O, Kowal K, Distler O, Rojewska J, Bodzenta-Lukaszyk A, et al. 2005. Cyclooxygenaseand lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum. 52:3783-911
145. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, et al. 2008. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem. Biophys. Res. Commun. 367:509-155
146. Bilal S, HaworthO,Wu L,Weylandt KH, Levy BD,Kang JX. 2011. Fat-1 transgenicmice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim. Biophys. Acta 1812:1164-699
147. Rogerio AP, Haworth O, Croze R, Oh SF, Uddin M, et al. 2012. Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J. Immunol. 189:1983-911
148. El Kebir D, Jozsef L, Khreiss T, PanW, Petasis NA, et al. 2007. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J. Immunol. 179:616-222
149. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, et al. 2007. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. 21:3877-844